Gyre Therapeutics (GYRE) Other Operating Expenses (2012 - 2026)

Gyre Therapeutics (GYRE) has 12 years of Other Operating Expenses data on file, last reported at $17.9 million in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $17.9 million, up 52.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.9 million (up 53.5% YoY), and the FY2025 annual result was -$4000.0, up 93.94% from the prior year.
• Other Operating Expenses improved to $17.9 million in Q1 2026 per GYRE's latest filing, from -$2000.0 in the prior quarter.
• Over five years, Other Operating Expenses peaked at $57.2 million in Q2 2022 and troughed at -$2.2 million in Q4 2023.
• A 5-year average of $7.3 million and a median of $500.0 in 2024 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Operating Expenses jumped 4925.9% in 2022, then plunged 3603.39% in 2023.
• A 5-year view of Other Operating Expenses shows it stood at -$59000.0 in 2022, then sank by 3603.39% to -$2.2 million in 2023, then soared by 100.09% to $2000.0 in 2024, then sank by 200.0% to -$2000.0 in 2025, then soared by 895900.0% to $17.9 million in 2026.
• Business Quant data shows GYRE's Other Operating Expenses at $17.9 million in Q1 2026, -$2000.0 in Q4 2025, and -$1000.0 in Q3 2025.